
Blood stem cell therapy maker Garuda nabs $62M
Garuda Therapeutics brought in $62 million via a Series B to take its off-the-shelf cell therapies into the clinic next year.
The Boston-area biotech wants to rid the need for blood stem cell transplants and instead give patients self-renewing blood stem cells. The proceeds, which add to a $72 million Series A from September 2021, will bankroll two lead programs in hematological and oncology indications, Garuda said Tuesday morning.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.